(-0.13%) 5 462.19 points
(-0.35%) 38 977 points
(0.22%) 17 757 points
(0.31%) $81.08
(-3.48%) $2.66
(-0.94%) $2 308.90
(-0.37%) $28.76
(1.46%) $1 000.80
(0.29%) $0.936
(0.78%) $10.69
(0.42%) $0.792
(-0.21%) $87.30
@ $110.53
発行日: 25 6月 2024 @ 01:19
リターン: -3.40%
前回のシグナル: 6月 22 - 04:01
前回のシグナル:
リターン: 3.23 %
Live Chart Being Loaded With Signals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally...
Stats | |
---|---|
本日の出来高 | 46 168 |
平均出来高 | 754 645 |
時価総額 | 6.73B |
EPS | $-0.230 ( Q1 | 2024-05-02 ) |
次の収益日 | ( $4.71 ) 2024-08-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
22.11 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $1.424 (1.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-07 | Carr Patricia | Sell | 163 | Ordinary Shares |
2024-05-03 | Patil Neena M | Sell | 5 000 | Ordinary Shares |
2024-04-05 | Gala Renee D | Sell | 1 736 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 1 236 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 700 | Ordinary Shares |
INSIDER POWER |
---|
42.47 |
Last 96 transactions |
Buy: 315 549 | Sell: 134 118 |
ボリューム 相関
Jazz Pharmaceuticals PLC 相関
10 最も負の相関 | |
---|---|
GALT | -0.861 |
GDST | -0.856 |
STOK | -0.848 |
IGLD | -0.844 |
PPTA | -0.84 |
LABP | -0.835 |
XLO | -0.835 |
SBNY | -0.828 |
STAA | -0.828 |
BLIN | -0.824 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Jazz Pharmaceuticals PLC 相関 - 通貨/商品
Jazz Pharmaceuticals PLC 財務諸表
Annual | 2023 |
収益: | $3.83B |
総利益: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2023 |
収益: | $3.83B |
総利益: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2022 |
収益: | $3.66B |
総利益: | $3.12B (85.23 %) |
EPS: | $-3.42 |
FY | 2021 |
収益: | $3.09B |
総利益: | $2.65B (85.76 %) |
EPS: | $-5.52 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。